Nov 2nd, 2009 - ChicagoTribune
TRENTON, N.J. (AP) - U.S. regulators have refused to accept drugmaker Merck & Co.'s application for a new, combination cholesterol pill that includes rival Pfizer's Lipitor, the world's top-selling drug.
Merck disclosed the rare move by the Food and Drug Administration in a regulatory filing Monday.
The company 2 1/2 years ago said it planned to make a dual cholesterol pill that at the time looked sure to be a blockbuster: a combination of Pfizer Inc.'s Lipitor - which generates nearly $13 billion in annual sales - and Zetia, a cholesterol pill Merck sells with Schering-Plough Corp. The two drugmakers have been partners on cholesterol medicines since 2000 and are about to merge.
Related stories:
Merck to complete $41B purchase of Schering-Plough
Nov 3rd, 2009 - Houston Chronicle
WHITEHOUSE STATION, N.J. — Merck & Co. is set to complete its $41 billion acquisition of Schering-Plough Corp. later Tuesday, creating the world's second-largest drugmaker...
FDA won't accept Merck's application for new drug
Nov 2nd, 2009 - Forbes
WHITEHOUSE STATION, N.J. -- U.S. regulators won't accept drugmaker Merck's application for a new combination cholesterol pill that includes rival Pfizer's Lipitor, the world's top-selling drug. Merck & Co...
Merck's buy of Schering-Plough gets FTC approval
Oct 29th, 2009 - Boston
NEW YORK—Merck & Co. and Schering-Plough Corp. said Thursday they have won merger approval from the Federal Trade Commission and antitrust regulators in Switzerland and Canada.
Freeport-McMoRan to move into S&P 100 index
Oct 29th, 2009 - sacbee
NEW YORK -- Standard & Poor's said Thursday it will add miner Freeport-McMoRan Copper & Gold Inc. to its S&P 100 index to replace Schering-Plough Corp., after the drugmaker merges with Merck & Co...
EU approves Merck's takeover of Schering-Plough
Oct 24th, 2009 - The Denver Post
BRUSSELS — The European Union approved Merck & Co.'s proposed takeover of Schering-Plough, which would create the second-biggest global producer of prescription medicines.



